These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38101437)

  • 1. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
    Wang M; Fan Y; Sun M; Wang Y; Zhao Y; Jin B; Hu Y; Han Z; Song X; Liu A; Tang K; Ding C; Liang L; Wu L; Gao J; Wang J; Cheng Y; Zhou J; He Y; Dong X; Yao Y; Yu Y; Wang H; Sun S; Huang J; Fang J; Li W; Wang L; Ren X; Zhou C; Hu Y; Zhao D; Yang R; Xu F; Huang Y; Pan Y; Cui J; Xu Y; Yang Z; Shi Y
    Lancet Respir Med; 2024 Mar; 12(3):217-224. PubMed ID: 38101437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
    Yu Y; Guo Q; Zhang Y; Fang J; Zhong D; Liu B; Pan P; Lv D; Wu L; Zhao Y; Li J; Liu Z; Liu C; Su H; Fan Y; Zhang T; Liu A; Jin B; Wang Y; Zhou J; Zhang Z; Ran F; Song X; Shi M; Su W; Lu S;
    Lancet Respir Med; 2024 Dec; 12(12):958-966. PubMed ID: 39270695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
    Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
    Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of KRASG12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study.
    Zhou Q; Meng X; Sun L; Huang D; Yang N; Yu Y; Zhao M; Zhuang W; Guo R; Hu Y; Pan Y; Shan J; Sun M; Yuan Y; Fan Y; Huang J; Liu L; Chu Q; Wang X; Xu C; Lin J; Huang J; Huang M; Sun J; Zhang S; Zhou H; Wu YL
    J Thorac Oncol; 2024 Dec; 19(12):1630-1639. PubMed ID: 39127176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
    Maruyama D; Jacobsen E; Porcu P; Allen P; Ishitsuka K; Kusumoto S; Narita T; Tobinai K; Foss F; Tsukasaki K; Feldman T; Imaizumi Y; Izutsu K; Morishima S; Yamauchi N; Yuda J; Brammer JE; Kawamata T; Ruan J; Nosaka K; Utsunomiya A; Wang J; Zain J; Kakurai Y; Yamauchi H; Hizukuri Y; Biserna N; Tachibana M; Inoue A; Horwitz SM
    Lancet Oncol; 2024 Dec; 25(12):1589-1601. PubMed ID: 39486432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
    Randon G; Lonardi S; Fassan M; Palermo F; Tamberi S; Giommoni E; Ceccon C; Di Donato S; Fornaro L; Brunetti O; De Vita F; Bittoni A; Chini C; Spallanzani A; Nappo F; Bethaz V; Strippoli A; Latiano T; Cardellino GG; Giuliani F; Morano F; Niger M; Raimondi A; Prisciandaro M; Pircher CC; Sciortino C; Marchesi S; Garattini SK; Airò G; Miceli R; Di Bartolomeo M; Pietrantonio F
    Lancet Oncol; 2024 Dec; 25(12):1539-1550. PubMed ID: 39557058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and activity of lenalidomide in combination with obinutuzumab in patients with relapsed indolent non-Hodgkin lymphoma: a single group, open-label, phase 1/2 trial.
    Gurumurthi A; Chin CK; Feng L; Fowler NH; Strati P; Hagemeister FB; Fayad LE; Westin JR; Obi C; Arafat J; Nair R; Steiner RE; Neelapu SS; Flowers CR; Nastoupil LJ
    EClinicalMedicine; 2024 Aug; 74():102747. PubMed ID: 39161543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment for women with postpartum iron deficiency anaemia.
    Jensen MCH; Holm C; Jørgensen KJ; Schroll JB
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD010861. PubMed ID: 39670550
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.